Skip to main content
SpringerLink
Log in

Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799–800.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.

    Article  CAS  PubMed  Google Scholar 

  3. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  PubMed  Google Scholar 

  5. Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14:456–67.

    Article  CAS  PubMed  Google Scholar 

  6. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  7. Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. World Health Organization classification of tumours, vol 3. Lyon: International Agency for Research on Cancer; 2010.

  8. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814–23.

    Article  CAS  PubMed  Google Scholar 

  10. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–52.

    Article  PubMed Central  PubMed  Google Scholar 

  11. NCCN. Neuroendocrine Tumors. 2014. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

  12. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.

    Article  CAS  PubMed  Google Scholar 

  13. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.

    PubMed  Google Scholar 

  14. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–92.

    CAS  PubMed  Google Scholar 

  15. Hanna N, Bunn Jr PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.

    Article  CAS  PubMed  Google Scholar 

  16. Kenmotsu H, Niho S, Ito T, et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Lung Cancer. 2014;84:254–8.

    Article  PubMed  Google Scholar 

  17. Ferrarotto R, Testa L, Riechelmann RP, et al. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare Tumors. 2013;5:e35.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637–42.

    Article  CAS  PubMed  Google Scholar 

  19. Kunz PL, TK, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA Ford, BaliseRR., G. A. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. ASCO Annual Meeting 2010.

  20. Venook A. P. AHK, M. A. Tempero, J. Uy, WeberT, Korn and Bergsland EK.. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008 2008 ASCO Annual Meeting Proceedings.

  21. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA

    Jason Zhu

  2. Department of GI Oncology, Neuroendocrine Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA

    Jonathan R. Strosberg

  3. Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, 27710, USA

    Evan Dropkin & John H. Strickler

Authors
  1. Jason Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan R. Strosberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evan Dropkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John H. Strickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John H. Strickler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, J., Strosberg, J.R., Dropkin, E. et al. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Canc 46, 166–169 (2015). https://doi.org/10.1007/s12029-015-9689-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9689-0

Keywords

Search

Navigation